01801.HK
Innovent Biologics, Inc.
HKSE · Healthcare · Biotechnology · CN
HKD 81.60
+0.43%Margins
Gross margin
81.0%
EBITDA margin
16.3%
EBIT margin
12.0%
Net margin
7.8%
FCF margin
83.4%
5.9%
Return on equity
2.9%
Return on assets
8.1%
Return on invested capital
0.39x
Asset turnover
HKD 15.8B
Cash from operations
HKD 26
Cash per share
Margins, returns on capital and operating efficiency from the latest trailing period · Data as of Jun 1, 2026